loading
Poseida Therapeutics Inc stock is traded at $2.73, with a volume of 362.67K. It is up +0.74% in the last 24 hours and up +9.20% over the past month. Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
See More
Previous Close:
$2.71
Open:
$2.71
24h Volume:
362.67K
Relative Volume:
0.76
Market Cap:
$271.93M
Revenue:
$64.70M
Net Income/Loss:
$-123.43M
P/E Ratio:
-11.38
EPS:
-0.24
Net Cash Flow:
$-95.23M
1W Performance:
-1.09%
1M Performance:
+9.20%
6M Performance:
-10.78%
1Y Performance:
+4.60%
1-Day Range:
Value
$2.69
$2.87
1-Week Range:
Value
$2.63
$2.98
52-Week Range:
Value
$1.87
$4.27

Poseida Therapeutics Inc Stock (PSTX) Company Profile

Name
Name
Poseida Therapeutics Inc
Name
Phone
858-779-3100
Name
Address
9390 TOWNE CENTRE DRIVE, SAN DIEGO
Name
Employee
350
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PSTX's Discussions on Twitter

Compare PSTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
PSTX 2.73 271.93M 64.70M -123.43M -95.23M -0.24
VRTX 450.97 116.38B 10.63B -479.80M -1.35B 13.33
REGN 738.00 82.09B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.14B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.25B 3.30B -501.07M 1.03B 11.54

Poseida Therapeutics Inc Stock (PSTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-04-23 Initiated H.C. Wainwright Buy
Jan-07-22 Initiated Cantor Fitzgerald Overweight
May-18-21 Initiated BTIG Research Buy
Aug-04-20 Initiated BofA Securities Buy
Aug-04-20 Initiated Piper Sandler Overweight
Aug-04-20 Initiated William Blair Outperform
View All

Poseida Therapeutics Inc Stock (PSTX) Latest News

pulisher
Nov 21, 2024

Poseida Therapeutics to Present at Two Upcoming Investor Conferences - Marketscreener.com

Nov 21, 2024
pulisher
Nov 21, 2024

Poseida Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 21, 2024
pulisher
Nov 19, 2024

Poseida Therapeutics (NASDAQ:PSTX) Earns Buy Rating from HC Wainwright - Defense World

Nov 19, 2024
pulisher
Nov 16, 2024

Poseida Therapeutics Provides Update on Cell Therapy Research ProgramsOn November 14, 2024, Poseida Therapeutics, Inc. issued a press release providing an update on its cell therapy research and development programs. Members of the management - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

Poseida Therapeutics offers preclinical highlights of CAR T pipeline - BioWorld Online

Nov 15, 2024
pulisher
Nov 15, 2024

Where Poseida Therapeutics Stands With Analysts - Benzinga

Nov 15, 2024
pulisher
Nov 15, 2024

Poseida Therapeutics (NASDAQ:PSTX) Receives "Buy" Rating from HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline - PR Newswire

Nov 14, 2024
pulisher
Nov 13, 2024

Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know - MSN

Nov 13, 2024
pulisher
Nov 12, 2024

Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Poseida Therapeutics’ (PSTX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Nov 12, 2024
pulisher
Nov 11, 2024

Poseida Therapeutics (PSTX) to Present at Major Stifel, Piper Sandler Healthcare Conferences | PSTX Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 09, 2024

HC Wainwright Reiterates Buy Rating for Poseida Therapeutics (NASDAQ:PSTX) - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Poseida Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve

Nov 08, 2024
pulisher
Nov 08, 2024

Poseida Therapeutics Reports Strong Q3 2024 Progress - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 - PR Newswire

Nov 07, 2024
pulisher
Nov 05, 2024

Poseida Therapeutics to present cancer cell therapy data at SITC, ASH - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 - Lelezard

Nov 05, 2024
pulisher
Nov 05, 2024

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 – Company AnnouncementFT.com - Financial Times

Nov 05, 2024
pulisher
Nov 01, 2024

Poseida Therapeutics (STU:2RZ) Degree of Operating Leverage : -9.17 (As of Jun. 2024) - GuruFocus.com

Nov 01, 2024
pulisher
Oct 30, 2024

Poseida Therapeutics' (PSTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 30, 2024
pulisher
Oct 26, 2024

Poseida Therapeutics Receives Regenerative Medicine Advanced The - GuruFocus.com

Oct 26, 2024
pulisher
Oct 24, 2024

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema - PR Newswire

Oct 24, 2024
pulisher
Oct 23, 2024

VRTX: 3 Pharma Stocks to Watch as Gene Therapy Gains Momentum - StockNews.com

Oct 23, 2024
pulisher
Oct 19, 2024

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30% - Simply Wall St

Oct 19, 2024
pulisher
Oct 18, 2024

Third development candidate nominated under Poseida and Roche’s allogeneic CAR T collaboration - BioWorld Online

Oct 18, 2024
pulisher
Oct 17, 2024

Poseida shares hold as analyst reiterates buy rating on MM study - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Poseida Nominates New Development Candidate Under Its Collaboration With Roche - Contract Pharma

Oct 17, 2024
pulisher
Oct 17, 2024

Poseida Therapeutics (NASDAQ:PSTX) Rating Reiterated by HC Wainwright - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Poseida advances with new CAR-T therapy candidate - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - StockTitan

Oct 17, 2024
pulisher
Oct 16, 2024

Quarterly Metrics: Quick and Current Ratios for Poseida Therapeutics Inc (PSTX) - The Dwinnex

Oct 16, 2024
pulisher
Oct 15, 2024

Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World

Oct 15, 2024
pulisher
Oct 15, 2024

MaxCyte Appoints Cynthia Collins to its Board of Directors - The Manila Times

Oct 15, 2024
pulisher
Oct 14, 2024

The Anatomy Of Astellas And Poseida's CAR-T Deal - In Vivo

Oct 14, 2024
pulisher
Oct 10, 2024

PSTXPoseida Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 10, 2024
pulisher
Oct 10, 2024

Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™

Oct 10, 2024
pulisher
Oct 07, 2024

Ratio Examination: Poseida Therapeutics Inc (PSTX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 07, 2024
pulisher
Oct 07, 2024

Poseida Therapeutics Inc (PSTX) deserves closer scrutiny - US Post News

Oct 07, 2024
pulisher
Oct 03, 2024

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - IT News Online

Oct 03, 2024
pulisher
Oct 03, 2024

Poseida Therapeutics (STU:2RZ) Long-Term Capital Lease Obli - GuruFocus.com

Oct 03, 2024
pulisher
Oct 03, 2024

Poseida Therapeutics (STU:2RZ) Net Change in Cash : €-18.49 Mil (TTM As of Jun. 2024) - GuruFocus.com

Oct 03, 2024
pulisher
Oct 03, 2024

Anchoring Your Portfolio: Is PSTX Stock a Safe Harbor? - The InvestChronicle

Oct 03, 2024
pulisher
Oct 02, 2024

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Acquired by Renaissance Technologies LLC - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

Roche-Poseida Lead Allogeneic CAR-T Advances after Showing Promise in Multiple Myeloma - Genetic Engineering & Biotechnology News

Oct 02, 2024
pulisher
Oct 01, 2024

A new trading data show Poseida Therapeutics Inc (PSTX) is showing positive returns. - SETE News

Oct 01, 2024
pulisher
Oct 01, 2024

Poseida stock supported by strong data from P-BCMA-ALLO-1, says BTIG - Investing.com South Africa

Oct 01, 2024
pulisher
Sep 30, 2024

Piper Sandler maintains Overweight rating on Poseida Therapeutics shares - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Poseida Therapeutics' SWOT analysis: gene therapy stock shows promise amid challenges - Investing.com India

Sep 30, 2024

Poseida Therapeutics Inc Stock (PSTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Cap:     |  Volume (24h):